>
Switch to:

Illumina Sloan Ratio %

: 0.00% (As of Mar. 2022)
View and export this data going back to 2000. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Illumina's Sloan Ratio for the quarter that ended in Mar. 2022 was 0.00%.

As of Mar. 2022, Illumina has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Illumina Sloan Ratio % Historical Data

The historical data trend for Illumina's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Sloan Ratio %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 21.51 -10.85 1.71 8.45

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Sloan Ratio % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.08 -18.51 8.90 - -

Competitive Comparison

For the Diagnostics & Research subindustry, Illumina's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Illumina Sloan Ratio % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Illumina's Sloan Ratio % falls into.



Illumina Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Illumina's Sloan Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2021 )-Cash Flow from Operations (A: Dec. 2021 )
-Cash Flow from Investing (A: Dec. 2021 ))/Total Assets (A: Dec. 2021 )
=(762-545
--1069)/15217
=8.45%

Illumina's Sloan Ratio for the quarter that ended in Mar. 2022 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM})
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2022 )
=(700-435
--2519)/15274
=18.23%

Illumina's Net Income for the trailing twelve months (TTM) ended in Mar. 2022 was 185 (Jun. 2021 ) + 317 (Sep. 2021 ) + 112 (Dec. 2021 ) + 86 (Mar. 2022 ) = $700 Mil.
Illumina's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2022 was 253 (Jun. 2021 ) + -272 (Sep. 2021 ) + 282 (Dec. 2021 ) + 172 (Mar. 2022 ) = $435 Mil.
Illumina's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2022 was 3 (Jun. 2021 ) + -2448 (Sep. 2021 ) + 0 (Dec. 2021 ) + -74 (Mar. 2022 ) = $-2,519 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Illumina  (NAS:ILMN) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2022, Illumina has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Illumina Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Illumina's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina Business Description

Illumina logo
Industry
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)